CO6470848A2 - Método de tratamiento contra la depresión - Google Patents

Método de tratamiento contra la depresión

Info

Publication number
CO6470848A2
CO6470848A2 CO11165136A CO11165136A CO6470848A2 CO 6470848 A2 CO6470848 A2 CO 6470848A2 CO 11165136 A CO11165136 A CO 11165136A CO 11165136 A CO11165136 A CO 11165136A CO 6470848 A2 CO6470848 A2 CO 6470848A2
Authority
CO
Colombia
Prior art keywords
depression
activity
treatment against
inhibit
receptors
Prior art date
Application number
CO11165136A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Breder
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of CO6470848A2 publication Critical patent/CO6470848A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO11165136A 2009-04-30 2011-11-30 Método de tratamiento contra la depresión CO6470848A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17408409P 2009-04-30 2009-04-30

Publications (1)

Publication Number Publication Date
CO6470848A2 true CO6470848A2 (es) 2012-06-29

Family

ID=43032555

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11165136A CO6470848A2 (es) 2009-04-30 2011-11-30 Método de tratamiento contra la depresión

Country Status (8)

Country Link
US (1) US20120115871A1 (https=)
EP (1) EP2424539A4 (https=)
JP (2) JP2012525426A (https=)
AU (1) AU2010242971A1 (https=)
CA (1) CA2760527A1 (https=)
CO (1) CO6470848A2 (https=)
MX (1) MX2011011579A (https=)
WO (1) WO2010127120A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260606A (en) * 1979-07-19 1981-04-07 A. H. Robins Company, Inc. 3-Methyleneazetidine derivatives
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
EP2341912B1 (en) * 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)

Also Published As

Publication number Publication date
MX2011011579A (es) 2012-01-27
WO2010127120A1 (en) 2010-11-04
AU2010242971A1 (en) 2011-11-24
JP2012525426A (ja) 2012-10-22
US20120115871A1 (en) 2012-05-10
CA2760527A1 (en) 2010-11-04
EP2424539A4 (en) 2012-09-19
JP2014240417A (ja) 2014-12-25
EP2424539A1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
CN111201039B (zh) 大麻二酚与5-ht2b受体激动剂安非他明的组合治疗癫痫的用途
Shelton Serotonin and norepinephrine reuptake inhibitors
Papakostas et al. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
Millan Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs
Borsini et al. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?
Wang et al. Vilazodone for the treatment of depression: an update
MX2009006304A (es) Nuevos compuestos de oxadiazol.
Bymaster et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: implications for treatment of attention‐deficit hyperactivity disorder
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
BRPI0810525B8 (pt) uso de pioglitazona ou rosiglitazona pra tratar a dependência em álcool, cocaína e nicotina, composições farmacêuticas e formas de dosagem, e combinações farmacêuticas contendo pioglitazona ou rosiglitazona
UY32238A (es) Agonistas de los receptores de la melanocortina
Bymaster et al. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
ECSP14009619A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EA201000280A1 (ru) Фармацевтические композиции, содержащие лиганды дофаминовых рецепторов, и способы лечения с помощью лигандов дофаминовых рецепторов
Peeters et al. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine
Bourin et al. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice
Florán et al. Activation of dopamine D4 receptors modulates [3H] GABA release in slices of the rat thalamic reticular nucleus
AR056839A1 (es) Metodos para la administracion transdermica de un agonista indol del receptor de serotonina y composiciones transdermicas para usar en los mismos
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
CO6470848A2 (es) Método de tratamiento contra la depresión
PE20090524A1 (es) Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
PE20060125A1 (es) Formas de dosificacion y composiciones farmaceuticas que comprenden 4-ciano-n-{(2r)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil]-n-piridin-2-il-benzamida y/o compuestos relacionados

Legal Events

Date Code Title Description
FC Application refused